

Enteroporc Coli AC

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued / amended on	Product Information affected ²	Summary ³
IAIN/0004/G	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	28/04/2021		Annex II and PL	The Agency accepted the grouping of variations to add three new manufacturers.
IB/0003	C.II.7.b - Introduction of a new Pharmacovigilance system - Which has been assessed by the relevant national competent authority/EMA for another product of the same MAH	15/04/2021	n/a		n/a
IB/0002	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	17/03/2021	n/a		n/a

¹ Notifications are issued for type I variations (unless part of a group including a type II variation or higher procedure or a worksharing application). Opinions are issued for all other procedures.

² SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

³ Since October 2019 summary information is no longer published for variations that do not impact upon the product information

T/0001	Transfer of Marketing Authorisation	03/02/2021	26/02/2021	SPC, Labelling and PL	The European Commission transferred the marketing authorisation from IDT Biologika GmbH, Germany to Ceva Santé Animale, France.
--------	-------------------------------------	------------	------------	-----------------------	---